Hsbc Holdings PLC Alnylam Pharmaceuticals, Inc. Transaction History

Hsbc Holdings PLC

$160 Billion
Q2 2024

A detailed history of Hsbc Holdings PLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 54,155 shares of ALNY stock, worth $14.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

54,155

Previous 74,131 26.95%

Holding current value

$14.9 Million

Previous $11.1 Million 18.78%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$143.31 - $247.0 $2.86 Million - $4.93 Million	-19,976 Reduced 26.95%	54,155 $13.2 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $4.39 Million - $5.93 Million	29,932 Added 67.72%	74,131 $11.1 Million
Q4 2023 Feb 12, 2024	BUY	$151.41 - $196.57 $1.36 Million - $1.77 Million	9,014 Added 25.62%	44,199 $8.46 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $769,831 - $954,118	4,508 Added 14.7%	35,185 $6.23 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $1.59 Million - $1.83 Million	-8,617 Reduced 21.93%	30,677 $5.83 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $1.2 Million - $1.55 Million	6,560 Added 20.04%	39,294 $7.87 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $493,324 - $641,643	-2,659 Reduced 7.51%	32,734 $7.78 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $2 Million - $3.36 Million	-14,468 Reduced 29.02%	35,393 $7.18 Million
Q2 2022 Aug 11, 2022	BUY	$120.42 - $169.29 $244,934 - $344,335	2,034 Added 4.25%	49,861 $7.27 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $825,016 - $1.13 Million	6,487 Added 15.69%	47,827 $7.82 Million
Q4 2021 Feb 11, 2022	BUY	$159.56 - $209.29 $2.01 Million - $2.64 Million	12,626 Added 43.97%	41,340 $7.01 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $170,429 - $208,560	1,004 Added 3.62%	28,714 $5.35 Million
Q2 2021 Aug 13, 2021	SELL	$128.63 - $176.89 $670,162 - $921,596	-5,210 Reduced 15.83%	27,710 $4.7 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $72,293 - $100,143	-570 Reduced 1.7%	32,920 $4.65 Million
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $145,719 - $174,195	-1,185 Reduced 3.42%	33,490 $4.35 Million
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $2.2 Million - $3 Million	18,154 Added 109.88%	34,675 $5.06 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $730,720 - $1.1 Million	7,012 Added 73.74%	16,521 $2.45 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $58,293 - $83,877	626 Added 7.05%	9,509 $1.04 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $5.66 Million - $9.44 Million	-75,959 Reduced 89.53%	8,883 $1.04 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $5.52 Million - $6.84 Million	77,872 Added 1117.25%	84,842 $6.82 Million
Q2 2019 Aug 13, 2019	SELL	$65.86 - $92.79 $92,533 - $130,369	-1,405 Reduced 16.78%	6,970 $506,000
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $8.13 Million - $10.4 Million	-111,705 Reduced 93.03%	8,375 $782,000
Q4 2018 Feb 13, 2019	BUY	$62.67 - $88.33 $6.85 Million - $9.65 Million	109,262 Added 1010.0%	120,080 $8.76 Million
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $667,602 - $935,726	-7,628 Reduced 41.35%	10,818 $946,000
Q2 2018 Aug 10, 2018	SELL	$88.31 - $107.8 $1.67 Million - $2.04 Million	-18,894 Reduced 50.6%	18,446 $1.82 Million
Q1 2018 May 11, 2018	BUY	$115.92 - $148.54 $3.22 Million - $4.13 Million	27,817 Added 292.1%	37,340 $4.45 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $1.09 Million - $1.33 Million	9,523 New	9,523 $1.21 Million
Q3 2017 Nov 14, 2017	SELL	$72.53 - $118.27 $1.3 Million - $2.12 Million	-17,908 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	17,908	17,908 $1.43 Million

Others Institutions Holding ALNY

# of Institutions

614

Shares Held

108M

Call Options Held

2.33M

Put Options Held

2.17M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Alnylam Pharmaceuticals, Inc. Transaction History